Avid Bioservices Inc (CDMO)

[nuke661]

Carboat,

Re: your statement of "But hypothetically if all of the censored were deceased very early (unlikely)...";

Why would it be unlikely? 2nd line NSCLC, and 90% stage 4, with the knowledge that this disease is one of the very worst and has on of the very shortest survival prognosis going. I would expect a trial for this disease and this composition of 2nd line and 90% stage 4 to have a high percentage of censored patients due to early death. As I understand it people are usually all out of options when they get into trials like this and its late in the game for them. It would be good to see a comparable trial's censored data to get a feel for this issue.